MABSOT
Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation
| Coordinatore | OPSONA THERAPEUTICS LIMITED
Organization address
address: ROOM 2 13 FIRST FLOOR I M M TRINITY CENTRE FOR HEALTH SICENCE ST JAMES HOSPITAL contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Sito del progetto | http://www.mabsot.eu/ |
| Totale costo | 7˙844˙900 € |
| EC contributo | 5˙929˙064 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-12-01 - 2014-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
OPSONA THERAPEUTICS LIMITED
Organization address
address: ROOM 2 13 FIRST FLOOR I M M TRINITY CENTRE FOR HEALTH SICENCE ST JAMES HOSPITAL contact info |
IE (DUBLIN) | coordinator | 2˙232˙195.00 |
| 2 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 1˙051˙131.00 |
| 3 |
INSTITUT CATALA DE LA SALUT
Organization address
address: GRAN VIA DE LES CORTS CATALANES 587 contact info |
ES (BARCELONA) | participant | 461˙648.00 |
| 4 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 449˙088.00 |
| 5 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 443˙599.00 |
| 6 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 427˙434.00 |
| 7 |
Nome Ente NON disponibile
Organization address
address: Videnska 1958/9 contact info |
CZ (PRAGUE 4) | participant | 353˙271.00 |
| 8 |
ALMAC DIAGNOSTICS LIMITED
Organization address
address: SEAGOE INDUSTRIAL ESTATE 20 contact info |
UK (CRAIGAVON) | participant | 261˙511.00 |
| 9 |
EURAM LIMITED
Organization address
address: "Tower House, Lucy Tower Street" contact info |
UK (LINCOLN) | participant | 249˙187.00 |
| 10 |
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203 contact info |
ES (L'HOSPITALET DE LLOBREGAT) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OPN-305) which has received OMP designation (EU/3/09/638) for use in the prevention of DGF. The scientific basis of this development is the inhibition of Toll-like receptor 2 (TLR2)-mediated ischaemic reperfusion injury which has a pivotal role in the pathogenesis of DGF and its sequelae. The MABSOT project is designed to progress the development of this OMP through Phase I and II clinical trial. The successful completion of the programme will allow the continued development of OPN-305 as an OMP for the treatment of DGF in a range of solid organ transplant situations. OPN-305 development will have significant benefit to these patients and health care providers in reducing the prolonged hospitalisation of these individuals, providing greater longevity associated with the transplanted organ and enhanced quality of life for these individuals.'
Introduzione (Teaser)
Delayed graft function (DGF) is a condition that often follows organ transplantation. A novel antibody treatment may prevent graft rejection following transplantation by targeting DGF.